Cite
HARVARD Citation
Keystone, E. et al. (2017). Patient-reported outcomes from a phase 3 study of baricitinib versus placebo or adalimumab in rheumatoid arthritis: secondary analyses from the RA-BEAM study. Annals of the rheumatic diseases. 76 (11), pp. 1853-1861. [Online].